| dc.contributor.author | Xuan, J | |
| dc.contributor.author | Pearson, RB | |
| dc.contributor.author | Sanij, E | |
| dc.date.accessioned | 2020-11-27T00:41:10Z | |
| dc.date.available | 2020-11-27T00:41:10Z | |
| dc.date.issued | 2020-09-02 | |
| dc.identifier | pii: 1805256 | |
| dc.identifier.citation | Xuan, J., Pearson, R. B. & Sanij, E. (2020). CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer. MOLECULAR & CELLULAR ONCOLOGY, 7 (6), https://doi.org/10.1080/23723556.2020.1805256. | |
| dc.identifier.issn | 2372-3556 | |
| dc.identifier.uri | http://hdl.handle.net/11343/252553 | |
| dc.description.abstract | Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general mechanism of chemotherapeutic resistance. | |
| dc.language | English | |
| dc.publisher | TAYLOR & FRANCIS INC | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
| dc.title | CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer | |
| dc.type | Journal Article | |
| dc.identifier.doi | 10.1080/23723556.2020.1805256 | |
| melbourne.affiliation.department | Sir Peter MacCallum Department of Oncology | |
| melbourne.source.title | Molecular & cellular oncology | |
| melbourne.source.volume | 7 | |
| melbourne.source.issue | 6 | |
| dc.rights.license | CC BY-NC-ND | |
| melbourne.elementsid | 1464407 | |
| melbourne.openaccess.pmc | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671053 | |
| melbourne.contributor.author | Sanij, Elaine | |
| dc.identifier.eissn | 2372-3556 | |
| melbourne.accessrights | Open Access | |
